Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.
Authors not listed
Clayton Sleep Insititute
Abstract
Eligible patients will undergo this open label initial safety and feasibility study investigating the use of 6 g/day sodium oxybate in mild AD. A total of 5 visits are included with this trial and total subject participation duration of 7-8 weeks. The screening phase will include an initial screening visit and a screening PSG night. After successful screening, subjects will complete a baseline PSG night and undergo a third PSG night to monitor initial safety and compliance with study drug at a dosage of 4.5 g/day of sodium oxybate. Thus the subject will undergo three consecutive nights of PSG in the sleep center. The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient. The remaining visit will occur at 6 weeks after baseline, with Treatment Visit 3 consisting of two consecutive nights of PSG. Participation will be complete after this visit. Phone follow-up will be made at one week post completion visits to assess any wash-out symptoms. Please refer to Figure for flow of the study design.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (n.d.). Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients. <em>Clayton Sleep Insititute</em>. https://clinicaltrials.gov/study/NCT00706186
Vancouver
Anonymous. Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients. Clayton Sleep Insititute.
BibTeX
@misc{anonndPhaseI,
title = {Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.},
author = {Anonymous},
journal = {Clayton Sleep Insititute},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Shanghai Mental Health Center 2026
Open access · US-GOV
A Phase I, Open-Label, Single-Center, Frequency-Escalation Study of the Safety, Tolerability, and Preliminary Efficacy of Neural Stem Cell-Derived Exosomes in Patients With Moderate-to-Severe Early-Onset Alzheimer's Disease
Beijing Friendship Hospital 2016
Open access · US-GOV
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease: A Multi-center Single-arm Study in China
Cassava Sciences, Inc. 2022
Open access · US-GOV
An Open-Label Extension of the PTI-125-04 Study Evaluating the Safety and Long-Term Treatment of Simufilam in Mild-to-Moderate Alzheimer's Disease Patients
David Marcinek 2025
Open access · US-GOV
Open-Label, Single-Arm Phase 2a Pilot Study to Evaluate the Safety and Tolerability of a Daily Subcutaneous Dose of Elamipretide in Older Adults
Novartis Pharmaceuticals 2012
Open access · US-GOV
A 52-week, Prospective, Multi-center, Open-label Study to Assess the Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Patients With Alzheimer's Dementia in a Controlled Titration Schedule
vTv Therapeutics 2016
Open access · US-GOV